Interim Report for the period January – June 2020
Continued performance according to plan Key events during the second quarter 2020 · BioArctic communicated that the mechanism of action for the AD1801 antibody project is linked to ApoE, which is the most common genetic risk factor for Alzheimer’s disease Key events after the period · BioArctic’s partner AbbVie has decided to stop recruitment for the Multiple Ascending Dose (MAD) part of the Phase 1 study of ABBV-0805 in Parkinson’s disease patients. A detailed plan to accelerate ABBV-0805 into a Phase 2 Proof of Concept study in Parkinson’s disease patients is currently